Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05003947 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IBD

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 10, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 3 to 2v5
  2. Start date changed from estimate of Nov 1, 2022 to Jun 11, 2022v4
  3. Start date: Feb 2022 to Nov 1, 2022
    • Study sites: 1 to 3
    • Study description expanded, about 30 words
    v3
  4. Start date: Oct 2021 to Feb 2022
    • Site contact updated
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of inflammatory bowel disease
Trial Details
NCT Number NCT05003947
Lead Sponsor The Foundation for Orthopaedics and Regenerative Medicine
Conditions
(from sponsor)		 Inflammatory Bowel Diseases
Related terms Inflammatory Bowel Diseases
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov